Non–Small Cell Lung Cancer, Version 6.2015

David S. Ettinger(University of Colorado Cancer Center), Douglas E. Wood(University of Colorado Cancer Center), Wallace Akerley(University of Utah), Lyudmila Bazhenova(University of Colorado Cancer Center), Hossein Borghaei(Fox Chase Cancer Center), David Ross Camidge(University of Colorado Denver), Richard T. Cheney(Roswell Park Comprehensive Cancer Center), Lucian R. Chirieac(Brigham and Women's Hospital), Thomas A. D’Amico(Cancer Institute (WIA)), Todd L. Demmy(Roswell Park Comprehensive Cancer Center), Thomas J. Dilling(University of Colorado Denver), M.C. Dobelbower(University of Colorado Cancer Center), Ramaswamy Govindan(Washington University in St. Louis), Frederic W. Grannis(University of Colorado Denver), Leora Horn(University of Colorado Denver), Thierry Jahan(University of Colorado Cancer Center), Ritsuko Komaki(University of Colorado Denver), Lee M. Krug(University of Colorado Cancer Center), Rudy P. Lackner(University of Colorado Denver), Michael Lanuti(University of Colorado Denver), Rogério Lilenbaum(Yale Cancer Center), Jules Lin(University of Colorado Cancer Center), Billy W. Loo(University of Colorado Denver), Renato Martins(Seattle Cancer Care Alliance), Gregory A. Otterson(University of Colorado Denver), Jyoti D. Patel(Northwestern University), Katherine M.W. Pisters(University of Colorado Cancer Center), Karen L. Reckamp(University of Colorado Denver), Gregory J. Riely(University of Colorado Denver), Eric Rohren(University of Colorado Denver), Steven E. Schild(Mayo Clinic), Theresa A. Shapiro(University of Colorado Cancer Center), Steven Swanson(University of Colorado Denver), Kurt W. Tauer(University of Colorado Cancer Center), Stephen C. Yang(University of Colorado Cancer Center), Kristina M. Gregory(National Comprehensive Cancer Network), Miranda Hughes(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
May 1, 2015
10.6004/jnccn.2015.0071
Cited by 487

Abstract

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.

Related Papers

No related papers found

Powered by citation graph analysis